The experimental antiviral drug MK-4482 significantly decreased levels of virus and disease damage in the lungs of hamsters treated for SARS-CoV-2 infection, according to a new study. MK-4482, delivered orally, is now in human clinical trials.
source https://www.sciencedaily.com/releases/2021/04/210416120127.htm
0 comments: